Premium
Cyproterone acetate, an alternative progestogen in postmenopausal hormone replacement therapy? Effects on serum lipids and lipoproteins
Author(s) -
JENSEN JYTTE,
RIIS BENTE JUEL,
CHRISTIANSEN CLAUS
Publication year - 1987
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1987.tb02340.x
Subject(s) - progestogen , cyproterone acetate , medicine , cyproterone , endocrinology , estradiol valerate , cholesterol , placebo , valerate , hormone , chemistry , androgen , biochemistry , butyrate , alternative medicine , pathology , fermentation
Summary. Serum lipids and lipoproteins were studied in 76 healthy postmenopausal women treated for 1 year with either oestradiol valerate sequentially combined with the anti‐androgenic progestogen cyproterone acetate (CPA) or placebo. The women were examined every 3 months between days 18 and 21 of the tablet cycle, where the progestogen had been added to the oestrogen for at least 6 days. Combined oestrogen‐CPA therapy resulted in significantly reduced levels of total serum cholesterol and LDL‐cholesterol at all examinations, but serum triglycerides and HDL‐cholesterol levels were similar in the two groups. Total serum cholesterol and LDL‐cholesterol were reduced by approximately 5% ( P <0.01) and 8% ( P <0.01), respectively, after 1 year of combined oestrogen‐CPA therapy in comparison with both the initial values and the placebo group but serum triglycerides and HDL‐cholesterol levels were unchanged in both groups.